IgNova files patent application on antibody against COVID-19

IgNova announced today that it has filed a patent application covering the use of passive immunization to control SARS-CoV-2 infection in humans. IgNova, a biopharmaceutical R&D start up, researches technology based on specific egg immunoglobulins (IgY).

The patented IgY binds the spike protein of SARS-CoV-2, neutralizing the virus when it enters the mouth or nose and, therefore, inhibiting the infection process. IgNova’s technology offers a safe, economical, and unlimited source of polyclonal antibodies to control SARS-CoV-2.

The IgY antibody technology has a wide range of applications such as chewable tablets, sprays, or mouthwash, offering instant protection against SARS-CoV-2. Additional applications, such as IgY-coated air filters and masks, could potentially support medical professionals and other at-risk professions. With antigen and antibody production as well as specific applications included in the patent, IgNova envisions an exhaustive IgY technology response to COVID-19.

“We are at the final research stage,” says Michael Gerrits, IgNova Managing Director, “working closely with scientific institutions and potential strategic partners to bring the technology to market. We have started initial testing with the objective to allow our partners to introduce IgNova technology based products to market in Q4 2020.”

IgNova’s patent is based on proprietary IgY technology, a process that involves immunizing chickens against target pathogens, extracting antibodies from eggs. IgY technology was developed in the 1980s to help control dental caries. In Japan, the technology is widely used both in food and human health applications. “Early research looks promising,” says IgNova Managing Director Tonchy Ugrinovic. “With the right scientific and production partners, IgNova targets a mass-marketable solution in Q4 of this year 2020.”

About IgNova

Founded in 2013, IgNova is a biopharmaceutical R&D start up that drives IgY technology innovation in accordance with stringent quality management and design control standards. At production sites in the US, Japan, and Europe, cutting-edge health and safety solutions are developed in close collaboration with industry partners.


Pia Becker

Tel: +49 4445 9868174

Mobile: +49 151 10464268

Email: contact@ignova.com



I want to receive press releases with the same keywords as this article:


Germany-health-science-IgNova GmbH


Health, medical treatment, pharmaceuticals


Europe, EU, NATO



Important notice

Subscribers please note that material bearing the label "PROTEXT" is not part of CTK's news service and is not to be published under the "CTK" label. Protext is a commercial service providing distribution of press releases from clients, who are identified in the text of Protext reports and who bear full responsibility for their contents.